Gilead Sciences (GILD) Cash & Current Investments (2009 - 2026)

Gilead Sciences has reported Cash & Current Investments for 18 years, with the latest figure at $7.6 billion in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments fell 3.57% year-over-year to $7.6 billion; the trailing twelve-month figure through Mar 2026 stood at $7.6 billion (down 3.57% YoY), and the FY2025 full-year result was $7.6 billion, down 23.61% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $7.6 billion, roughly flat from $7.6 billion in the prior quarter.
• The five-year high for Cash & Current Investments was $10.0 billion in Q4 2024, with the low at $2.8 billion in Q2 2024.
• Historically, Cash & Current Investments has averaged $6.4 billion across 5 years, with a median of $6.4 billion in 2022.
• Annual changes were most pronounced in 2024 — Cash & Current Investments tumbled 58.42% — and 2025, when it surged 88.06%.
• Gilead Sciences' Cash & Current Investments stood at $6.4 billion in 2022, then advanced by 13.77% to $7.3 billion in 2023, then soared by 37.54% to $10.0 billion in 2024, then decreased by 23.61% to $7.6 billion in 2025, then climbed by 0.14% to $7.6 billion in 2026.
• The last three Cash & Current Investments figures came in at $7.6 billion (Q1 2026), $7.6 billion (Q4 2025), and $7.3 billion (Q3 2025), per Business Quant data.